Changes in glucose metabolism and metabolic outcomes following ETI initiation in patients with cystic fibrosis

Clicks: 9
ID: 337349
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #437 of 449 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 449 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Cystic fibrosis-related diabetes (CFRD) is a frequent complication in people with cystic fibrosis (pwCF). CFTR modulators such as Elexacaftor/Tezacaftor/Ivacaftor improve pulmonary outcomes, but their effect on glucose metabolism remains uncertain. This study evaluated changes in oral glucose tolerance after initiation of ETI. METHODS: In this uncontrolled retrospective single-center study, pwCF aged ≥10 years receiving ETI underwent a 2-hour oral glucose tolerance test before treatment, at 12 and 24 months. Participants were classified by baseline glucose tolerance: normal glucose tolerance (NGT), impaired glucose tolerance (IGT), or CFRD. Secondary outcomes included changes in body weight, FEV1, lipids, and HbA1c. RESULTS: Of 68 pwCF (median age 23 years), 56% had NGT, 25% IGT, and 19% CFRD at baseline. Among 62 participants with OGTT data at baseline and 24 months, glucose tolerance remained stable in 48 (77%), improved in 10 (16%), and worsened in 4 (6%). Median HbA1c decreased from 5.5% to 5.3% (P<0.001). In 52 adults, median body weight increased by +7.3 kg (P<0.001). At year 1, pwCF with deteriorated OGTT showed a greater increase in total cholesterol compared with those with stable or improved OGTT (+26 vs. +5 mg/dL, P=0.008). CONCLUSIONS: Glucose tolerance improved in some pwCF after ETI initiation, but responses were heterogeneous and improvements were not consistently sustained. A greater cholesterol increase in a small exploratory subgroup with worsening glucose tolerance requires confirmation.
Reference Key
openalex_W7223829069 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Floor Bracquez, Aster K. Desouter, Stefanie Vincken, Eef Vanderhelst, Elke De Wachter, A. Papaleo, Robert Hilbrands
Are you one of these authors? Claim your profile
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag437
URL
https://doi.org/10.1210/clinem/dgag437
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.